DMP.DE
Strong BuyUnloved QualityDermapharm Holding SE · Healthcare · Germany · $2.2B
EUR 37.50 -2.5% · close 2 Oct · scored 6 Oct
StockRank up 1.9 since 3 Oct.
Unloved Quality: Strong and cheap; the market has not turned yet.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
ABOUT DERMAPHARM HOLDING SE
Read
Dermapharm Holding SE is a leading manufacturer of branded pharmaceuticals and dermocosmetics in Germany, specializing in allergy therapeutics, traditional herbal medicines, and dermatological products. The company's competitive moat includes a strong brand portfolio, a direct-to-pharmacy sales network, and a focus on niche therapeutic areas, enabling stable market positions and predictable demand. Dermapharm is a vertically integrated pharmaceutical company, controlling the entire value chain from product development and manufacturing to distribution and marketing, primarily in the DACH region.
FINANCIAL SUMMARY (EUR)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 942.9M | 1.0B | 1.1B | 1.2B | 1.2B | 5.4% | 1.2B | 1.2B | 1.3B | 3.8% |
| EPS (EUR) | 3.89 | 2.49 | 1.16 | 2.11 | 2.46 | -10.8% | 2.78 | 2.52 | 2.86 | 7.8% |
| Shares | 53.8M | 53.8M | 53.8M | 53.8M | 53.8M | 0.0% | 49.5M | — | — | — |
| Debt | 580.3M | 4.9M | 1.1B | 979.6M | 1.1B | 16.0% | 1.2B | — | — | — |
| Equity | 497.3M | 531.6M | 539.2M | 604.4M | 694.4M | 8.7% | — | — | — | — |
| Op CF | 250.4M | 288.5M | 219.4M | 201.4M | 229.1M | -2.2% | 265.6M | — | — | — |
| Inv CF | -129.3M | -99.0M | -415.4M | -29.6M | -98.2M | — | — | — | — | — |
| Fin CF | -81.0M | -199.8M | 204.5M | -209.2M | -46.1M | — | — | — | — | — |
Calmer than 71% of stocks we rank over the past year (30% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DMP.DE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| DMP.DE | Dermapharm Holding SE(you) | $2.2B | 87 | Strong Buy |
| MRK.DE | Merck KGaA | $65.8B | 79 | Buy |
| EVT.DE | Evotec SE | $567M | 26 | Sell |
| DRW8.DE | Drägerwerk AG & Co. KGaA | $1.9B | 99 | Strong Buy |
| AFX.DE | Carl Zeiss Meditec AG | $3.1B | 77 | Buy |
| RHK.DE | RHÖN-KLINIKUM Aktiengesellschaft | $1.1B | 83 | Strong Buy |
| FIE.DE | Fielmann Group AG | $3.6B | 75 | Buy |
| EUZ.DE | Eckert & Ziegler SE | $881M | 79 | Buy |
| FMS | Fresenius Medical Care AG | $11.9B | 91 | Strong Buy |
| M12.DE | M1 Kliniken AG | $417M | 98 | Strong Buy |
Peer medians: ROE 3.3% · P/E 19.3x · Gross margin 45.7%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.